FRE Stock Overview
A health care company, provides products and services for chronically ill patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Fresenius SE & Co. KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €33.36 |
| 52 Week High | €35.85 |
| 52 Week Low | €24.42 |
| Beta | 1.04 |
| 11 Month Change | -1.74% |
| 3 Month Change | 0.45% |
| 1 Year Change | 18.09% |
| 33 Year Change | -1.36% |
| 5 Year Change | -31.46% |
| Change since IPO | -58.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| FRE | AT Healthcare | AT Market | |
|---|---|---|---|
| 7D | 1.6% | 0.3% | -0.6% |
| 1Y | 18.1% | -32.5% | 2.5% |
Return vs Industry: FRE exceeded the Austrian Healthcare industry which returned -32.5% over the past year.
Return vs Market: FRE exceeded the Austrian Market which returned 2.5% over the past year.
Price Volatility
| FRE volatility | |
|---|---|
| FRE Average Weekly Movement | 2.8% |
| Healthcare Industry Average Movement | 4.1% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in AT Market | 6.6% |
| 10% least volatile stocks in AT Market | 1.8% |
Stable Share Price: FRE has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: FRE's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1912 | 177,091 | Michael Sen | www.fresenius.com |
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Fresenius SE & Co. KGaA Fundamentals Summary
| FRE fundamental statistics | |
|---|---|
| Market cap | €18.79b |
| Earnings (TTM) | -€479.00m |
| Revenue (TTM) | €22.81b |
0.8x
P/S Ratio-39.2x
P/E RatioIs FRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FRE income statement (TTM) | |
|---|---|
| Revenue | €22.81b |
| Cost of Revenue | €17.48b |
| Gross Profit | €5.33b |
| Other Expenses | €5.81b |
| Earnings | -€479.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.85 |
| Gross Margin | 23.37% |
| Net Profit Margin | -2.10% |
| Debt/Equity Ratio | 60.9% |
How did FRE perform over the long term?
See historical performance and comparison